-
Repaglinide
- indication:For the treatment of Type II diabetes mellitus.
- pharmacologypharmacology:
- mechanism: Repaglinide closes ATP-dependent potassium channels in the b-cell membrane by binding at characterizable sites. This potassium channel blockade depolarizes the b-cell, which leads to an opening of calcium channels. The resulting increased calcium influx induces insulin secretion. The ion channel mechanism is highly tissue selective with low affinity for heart and skeletal muscle.
- toxicity: LD<sub>50</sub> >1 g/kg (rat) (W. Grell)
- absorprion: Rapid (bioavailability is 56%)
- halflife: 1 hour
- roouteelimination:
- volumedistribution:
- clearance: